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Background: Interleukin (IL)-32 is a described intracellular pluripotent pro-inflammatory mediator, characterized by
the signaling of NF-κB and STAT3.
Methods: Our study investigated whether IL-32 expression has clinical significance in the metastases of colorectal
cancer (CRC). A total of 70 CRC patients were enrolled, 47 cases of which were single CRC organic metastasis lesions
while the rest of which were primary CRC lesions (T4NxM0). IL-32 expression was detected by immunohistochemistry,
and the correlation between IL-32 expression and CRC metastases was analyzed.
Results: The positive rates of IL-32 in the CRC organic metastasis group were more severe than those in the primary CRC
group (P < 0.05). The positive rate of IL-32 in primary CRC with lymph node metastasis was more severe than that of IL-32
in primary CRC without lymph node metastasis (P < 0.05).
Conclusions: The level of IL-32 expression could influence the N grade of CRC. Thus, IL-32 expression may stimulate the
organic metastasis and the lymph node metastasis of CRC.
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Colorectal cancer (CRC) is the one of the most com-
mon malignancy tumor worldwide and the fourth
common cause of death of cancer [1]. It is estimated
that CRC will cause more than 500,000 all over the
world in 2013 [2]. A large amount of patients are
initially diagnosed with develop stage IV CRC [3].
With the therapeutic development for CRC, the over-
all survival keeps on increasing, but the treatment of
patients with metastasized CRC still remains a chal-
lenge [4,5], and the underlying mechanism is actually
unsolved [6,7]. As a result, it is always the main focus
of clinical medicine to find the biomarker of CRC
metastasis.
Cytokines are known to be involved in not only in-
flammation but also tumor development and progres-
sion [8]. Several researches have suggested that many
cytokines (such as IL-10, IL-17, IL-22, IL-23, and IL-35)
may have clinical significance in CRC [9-11].Interleukin-* Correspondence: 07301010200@fudan.edu.cn; zongyouchen@hotmail.com
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unless otherwise stated.32 (IL-32) is recognized as an intracellular pluripotent
pro-inflammatory mediator firstly [12]. IL-32 can stimu-
late immunosuppressive immunocytes and lead to the
raising of various cytokine expressions in stromal cells
[13-15]. And soon, it was confirmed to be the promoted
factor in the carcinogenesis of several solid tumors, such
as gastric cancer, pancreatic cancer, and lung cancer
[16-18].However, its expression has not been reported in
CRC metastasis. In our study, IL-32 expression in cancer
cells was immunohistologically evaluated, and the clin-
ical implications of IL-32 positivity with CRC metastasis
were analyzed and discussed.Methods
Patients and specimens
We retrospectively collected 70 consecutive patients
with CRC, 47 cases of which were CRC organic metas-
tasis lesions while the rest of which were primary CRC
lesions (T4NxM0). All of them underwent surgery
from 2000 to 2013 at Huashan Hospital, Fudan Uni-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,







Primary lesions 23 32.86a
Brain 19 27.24a
Liver 11 15.71a
Other distant metastasis 17 24.29a
aThe rate is calculated on the metastasis population.
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operative chemotherapy. The patient private identifi-
cation information was deleted, and informed consent
was obtained from all the patients. Clinical factors
were assessed by the Medical Ethics Committee of
Huashan Hospital.Immunohistochemistry
From paraffin blocks, the selected tissue was assessed
on 4-μm sections on an automatic platform (Dako
Immunostainer RM2145, Dako Corp., Copenhagen,
USA). The samples were obtained from the 70 pa-
tients. Antigen retrieval was finished by microwaving
in 10 mm citric acid monohydrate for 1 × 5 min at
900 W and for 3 × 5 min at 600 W. Sections were
treated with 0.3% H2O2 for 30 min in order to block
endogenous tissue peroxidase. The reaction was visu-
alized by the Envision kit (Dako Corp., Copenhagen,
Denmark) for IL-32 (ab37158, Abcam, Tokyo, Japan).
The antibody was obtained from R&D Systems and
used at the dilution of 1:200, being incubated with the
tissue sections at 37°C for 1 h. Splenic tissue was used
as a positive control for IL-32 expression. The positive
control was included in each run. The optical density
(OD) value of the tumor cell staining was measured
for quantitative analysis.Table 2 IL-32 expression and immunohistochemical score of p
IL-32 Primary lesions Brain metastasis
N % N %
0 9 39.13 5 26.32
1+ 7 30.43 2 10.52
2+ 2 8.70 5 26.32
3+ 5 21.74 7 36.84Three experienced pathologists independently evalu-
ated IL-32-stained slides without the knowledge of pa-
tient clinicopathologic information. The intensity and
percentage of immunoreactivity was scored on a scale of
0 to 3+. Membrane staining in less than 10% of invasive
tumor cells was scored as 0; faint/barely perceptive
membrane staining was detected in 10% of tumor cells
was scored as 1+; weak to moderate complete reactivity
in more than 10% tumor cells or <30% was scored as 2+;
strong complete reactivity in 10% or more of tumor cells
was scored as 3+. A score of 0 or 1+ was considered
negative while scores 2+ and 3+ were positive.
Statistical analysis
Statistical analysis was performed by χ2 tests, and the re-
sults are considered to be statistically significantly differ-
ent when P value is less than 0.05. The frequencies of
variables are described in percentages. All analyses are
performed using the SPSS version 19.0 software for
Windows (SPSS Inc., Chicago, IL, USA).
Results
Samples
All 70 CRC patients were considered eligible and in-
cluded in our analysis. Median age at time of metastasis
resection or radical operation was 61 years (41 to 87);
47.14% patients were males and 52.86% females. The
cases with other organic metastases include seven cases
of peritoneal metastasis, four cases of ovarian metasta-
ses, three cases of great omentum metastasis, one case
of gum metastasis, one case of osseous metastasis, and
one case of bladder metastasis. Patients’ clinical charac-
teristics are summarized in Table 1.
The relationship between IL-32 and organic metastasis of CRC
Immunohistochemistry (IHC) IL-32 expression pattern
is described in Table 2: 22 cases score 0 (31.44%), 12
cases score 1+ (17.14%), 18 cases score 2+ (25.71%), and
18 cases score 3+ (25.71%). Figure 1 shows the compari-
son of the IHC slides for IL-32.
Here, IHC IL-32 expression pattern of primary lesions
is compared with brain metastasis, liver metastasis, and
other metastasis. The results were considered to berimary lesions and other metastasis
Liver metastasis Other distant metastasis
N % N %
1 9.10 7 41.18
3 27.27 0 0.00
3 27.27 8 47.06
4 36.36 2 11.76
Figure 1 IL-32 staining scored 0 (A); IL-32 staining scored 1+ (B);
IL-32 staining scored 2+ (C); and IL-32 staining scored 3+ (D)
magnification × 100.
Table 4 Comparison of IL-32 expression between N−/N+
primary lesions of CRC
Samples Positive N(%) Negative N(%) P value
No lymph node metastasis 1(7.69) 12(92.21) 0.0000
Lymph node metastasis 6(60) 4(40)
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(Table 3).
The relationship between IL-32 and lymph node metasta-
sis of CRC
Here, IHC IL-32 expression pattern of primary lesions
with no lymph node metastasis was compared with pri-
mary lesions with lymph node metastasis. The results
were considered to be statistically significantly different
(P < 0.05), respectively, (Table 4).
Here, the main OD values of different grades of
lymph node metastasis (N grade, according to NCCN
colorectal cancer practice guideline 2012) were com-
pared altogether. The results showed that the OD
value had the trend of rising with the level-up of N
grade (Table 5, Figure 2).
Discussions
Several researches suggested that cytokines may be in-
volved in the proliferation, metastasis, and preventing
from antitumor cellular immunity [19-21]. Recent study
showed that IL-32 can affect the signaling of NF-κB and
STAT3 [22-24], which are confirmed to be the antiapop-
totic and pro-angiogenic genes in cancer developmentTable 3 Comparison of IL-32 expression between primary
lesions and different metastases of CRC
Samples Positive N(%) Negative N(%) P value
Primary lesions 7(30.44) 16(69.56) 0.0103
Brain metastasis 12(63.16) 7(36.84)
Primary lesions 7(30.44) 16(69.56) 0.0013
Liver metastasis 7(63.63) 4(36.37)
Primary lesions 7(30.44) 16(69.56) 0.0102
Other distant metastasis 10(58.82) 7(41.18)[25]. Carmi et al. [26] suggested that IL-32 can promote
angiogenesis and counterbalance the inflammation and
antitumor immunity. Seo et al. [27] measured serum IL-
32 levels of gastric cancer by ELISA and immunostain-
ing, finding significantly higher levels of IL-32 to those
of healthy volunteers. In this study, we demonstrate the
association of between IL-32 and different metastases of
CRC, aiming at finding new therapeutic direction for
CRC metastasis.
IL-32 and organic metastasis of CRC
IL-32 expression in tumor cells has been confirmed
mainly occurring in the advanced stages of cancers
[16,18]. But the relationship between IL-32 status and
CRC organic metastasis has not been clarified. Our re-
search aimed to describe the influence of IL-32 on CRC
organic metastasis, to compare the IL-32 expression in
primary lesions or organic metastasis, so as to find the
biological mark of CRC organic metastasis.
As determined by our analysis of 70 CRC patients,
IL-32 expression correlated with the organic metasta-
sis of CRC. The rate of IL-32-positive cases of CRC
primary lesions was 30.4%, while brain metastasis
63.16%, liver metastasis 63.63%, and other organic
metastasis 58.82%. The positive rates of CRC brain
metastasis, liver metastasis, and other distant metasta-
sis were similar. There were great differences between
the results of the rate of IL-32-positive cases of
CRC primary lesions and different organic metastases
(Table 3). As a result, IL-32 supposed to be the non-
specific mark of CRC organic metastasis.
IL-32 and lymph node metastasis of CRC
It has been suggested that IL-32-positive expression
was frequently associated with lymph node metastasis
in gastric cancer and lung cancer [16,18]. But there
is still no evidence whether there is association
between IL-32 expression and CRC lymph node me-
tastasis. Our research is here to analyze the IL-32Table 5 N grade of primary CRC and mean OD value
N grade N % Mean OD value
0 13 56.52 10.31
1 6 26.08 12.33
2 2 8.70 14.50
3 2 8.70 18.50
Figure 2 The relationship between N grade of primary CRC and OD value.
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to check whether IL-32 relates to CRC lymph node
metastasis.
The result showed that the rate of IL-32-positive
cases of CRC lymph node metastases was 60%, much
higher than those without lymph node metastasis. The
results were considered to be statistically significantly
different (Table 4). The tendency showed that the level
of IL-32 expression may influence the N grade of CRC
(Table 5, Figure 2). Further study with larger sample
size of the primary lesion population should be made
for exactly evidence.Conclusions
In conclusion, this research raises the concept of an
important role of IL-32 in CRC. Over-expression of
IL-32 may stimulate the organic metastasis and the
lymph node metastasis of CRC. IL-32 was confirmed
to be the biological mark for CRC metastasis. In
CRC, this result may promote the therapeutic poten-
tial for CRC metastasis. However, there are still sev-
eral aspects of IL-32 remaining elusive. Our study
also presents some limitations. The follow-up of the
patients has not finished yet. Further analysis on lar-
ger populations is required to support the results of
this study. And also, further researches should be
taken out to clarify the underlying pathway of IL-32,
so as to propose a new clinical therapy for CRC me-
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